Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Discontinued OperationsCash from Discontinued OperationsCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionDivestmentsExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Depreciation ExpenseEBIATLeasesNon-Current ReceivablesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsReceivables - OtherShares IssuedShares OutstandingShares OutstandingWages, Salaries and Other
Ratios

AC Immune (ACIU) Long-Term Debt Issuances (2017 - 2019)

AC Immune (ACIU) reported Long-Term Debt Issuances of $99017.6 for Q4 2019, up 97.08% year-over-year from $50241.7 in Q4 2018, and up 100.2% on a QoQ basis from -$50.0 million in Q2 2019.

AC Immune (ACIU) has 3 years of Long-Term Debt Issuances data on file, last reported at $99017.6 in Q4 2019.

  • Quarterly Long-Term Debt Issuances rose 97.08% year-over-year to $99017.6 in Q4 2019, while the trailing twelve-month figure through Dec 2019 was $539354.9 (changed N/A YoY) and the FY2021 annual result came in at $25.7 million, changed N/A from the prior year.
  • Long-Term Debt Issuances advanced to $99017.6 in Q4 2019 per ACIU's latest filing, from -$50.0 million in the prior quarter.
  • Across five years, Long-Term Debt Issuances topped out at $103.9 million in Q3 2017 and bottomed at -$101.2 million in Q4 2017.
  • The 3-year median for Long-Term Debt Issuances is $74629.7 (2018), against an average of $551911.8.
  • The widest annual swing landed in 2018, when Long-Term Debt Issuances surged 100.05%; it then jumped 97.08% in 2019.
  • Tracing ACIU's Long-Term Debt Issuances over 3 years: stood at -$101.2 million in 2017, then surged by 100.05% to $50241.7 in 2018, then jumped by 97.08% to $99017.6 in 2019.
  • Per Business Quant, the three latest ACIU Long-Term Debt Issuances figures stand at $99017.6 (Q4 2019), -$50.0 million (Q2 2019), and $50.5 million (Q1 2019).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Long-Term Debt Issuances (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - 2.73 Mn
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn -
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - -
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn -
7 Evaxion A 62.56 Bn 62.54 Bn - -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn -
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn -
10 AC Immune 325.88 Mn 211.53 Mn - -

Historic Data

Download Data 🔒
DateValue
Dec 31, 2019 99,017.60
Dec 31, 2019 99,017.60
Jun 30, 2019 -50.04 Mn
Jun 30, 2019 -50.04 Mn
Mar 31, 2019 50.48 Mn
Mar 31, 2019 50.48 Mn
Dec 31, 2018 50,241.74
Dec 31, 2018 50,241.74
Dec 31, 2017 -101.16 Mn
Dec 31, 2017 -101.16 Mn
Sep 30, 2017 103.88 Mn
Sep 30, 2017 103.88 Mn